| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 65 | 2024 | 1485 | 7.770 |
Why?
|
| Immunoconjugates | 21 | 2023 | 314 | 3.620 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 13 | 2023 | 192 | 2.820 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 77 | 2024 | 16640 | 2.360 |
Why?
|
| Ki-1 Antigen | 10 | 2022 | 186 | 2.270 |
Why?
|
| Lymphoma | 14 | 2019 | 1517 | 1.860 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 2017 | 235 | 1.670 |
Why?
|
| Lymphoma, Non-Hodgkin | 11 | 2019 | 1066 | 1.520 |
Why?
|
| Rituximab | 28 | 2022 | 1590 | 1.300 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 9 | 2022 | 389 | 1.240 |
Why?
|
| Doxorubicin | 36 | 2023 | 3142 | 1.060 |
Why?
|
| Lymphoma, T-Cell | 6 | 2019 | 366 | 0.930 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 14 | 2022 | 1737 | 0.870 |
Why?
|
| Mediastinal Neoplasms | 5 | 2019 | 427 | 0.830 |
Why?
|
| Vincristine | 19 | 2022 | 1581 | 0.820 |
Why?
|
| Prednisone | 16 | 2023 | 1031 | 0.820 |
Why?
|
| Cyclophosphamide | 23 | 2023 | 3242 | 0.800 |
Why?
|
| Adult | 109 | 2024 | 81689 | 0.780 |
Why?
|
| Young Adult | 63 | 2024 | 22134 | 0.780 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 12 | 2017 | 878 | 0.770 |
Why?
|
| Lymphocytes | 2 | 2017 | 1272 | 0.710 |
Why?
|
| Treatment Outcome | 56 | 2021 | 33691 | 0.690 |
Why?
|
| Vinblastine | 18 | 2023 | 462 | 0.670 |
Why?
|
| Neoplasm Staging | 35 | 2023 | 13996 | 0.670 |
Why?
|
| Disease-Free Survival | 32 | 2019 | 10258 | 0.660 |
Why?
|
| Leukocyte Count | 2 | 2017 | 724 | 0.660 |
Why?
|
| Bleomycin | 16 | 2023 | 482 | 0.650 |
Why?
|
| Recurrence | 28 | 2020 | 4872 | 0.640 |
Why?
|
| Middle Aged | 103 | 2023 | 90030 | 0.640 |
Why?
|
| Sirolimus | 3 | 2020 | 831 | 0.640 |
Why?
|
| Lymphoma, Follicular | 8 | 2020 | 636 | 0.630 |
Why?
|
| Everolimus | 2 | 2020 | 436 | 0.630 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 364 | 0.620 |
Why?
|
| Aged | 89 | 2022 | 73127 | 0.620 |
Why?
|
| Humans | 155 | 2024 | 270033 | 0.610 |
Why?
|
| Etoposide | 12 | 2020 | 905 | 0.610 |
Why?
|
| Antineoplastic Agents | 17 | 2021 | 14615 | 0.590 |
Why?
|
| Lymphoma, B-Cell | 8 | 2018 | 928 | 0.580 |
Why?
|
| Female | 109 | 2023 | 148486 | 0.570 |
Why?
|
| Salvage Therapy | 14 | 2018 | 2122 | 0.570 |
Why?
|
| Male | 103 | 2023 | 127917 | 0.570 |
Why?
|
| Platelet Count | 1 | 2017 | 490 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2022 | 10382 | 0.530 |
Why?
|
| Neutrophils | 2 | 2017 | 834 | 0.530 |
Why?
|
| Aged, 80 and over | 43 | 2020 | 30923 | 0.530 |
Why?
|
| Dacarbazine | 16 | 2023 | 502 | 0.520 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 107 | 0.500 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 1564 | 0.490 |
Why?
|
| Adolescent | 44 | 2024 | 32647 | 0.480 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 18 | 2022 | 7009 | 0.470 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 4 | 2019 | 320 | 0.470 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2018 | 6254 | 0.460 |
Why?
|
| Survival Rate | 21 | 2024 | 12508 | 0.440 |
Why?
|
| Radiotherapy | 4 | 2017 | 1858 | 0.440 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 280 | 0.440 |
Why?
|
| Blood Platelets | 1 | 2017 | 671 | 0.430 |
Why?
|
| CD40 Antigens | 1 | 2013 | 106 | 0.430 |
Why?
|
| B-Lymphocytes | 4 | 2019 | 1423 | 0.420 |
Why?
|
| Positron-Emission Tomography | 12 | 2023 | 2196 | 0.420 |
Why?
|
| Stem Cell Transplantation | 8 | 2020 | 1413 | 0.410 |
Why?
|
| Radiotherapy, Intensity-Modulated | 6 | 2018 | 2161 | 0.390 |
Why?
|
| Positron Emission Tomography Computed Tomography | 6 | 2023 | 880 | 0.390 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1726 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2019 | 3398 | 0.370 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2020 | 617 | 0.360 |
Why?
|
| Combined Modality Therapy | 16 | 2017 | 9040 | 0.360 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2018 | 749 | 0.360 |
Why?
|
| Follow-Up Studies | 24 | 2021 | 15172 | 0.360 |
Why?
|
| Drug Administration Schedule | 14 | 2021 | 3523 | 0.350 |
Why?
|
| Gene Expression | 2 | 2018 | 3630 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 7 | 2020 | 4463 | 0.330 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2018 | 551 | 0.310 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2020 | 1335 | 0.300 |
Why?
|
| Prognosis | 19 | 2024 | 22451 | 0.300 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2018 | 5405 | 0.300 |
Why?
|
| Retrospective Studies | 29 | 2023 | 39736 | 0.300 |
Why?
|
| Survival Analysis | 14 | 2023 | 9288 | 0.290 |
Why?
|
| Clinical Decision-Making | 2 | 2023 | 530 | 0.280 |
Why?
|
| Breast Implants | 3 | 2017 | 375 | 0.280 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 304 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2020 | 5061 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 207 | 0.270 |
Why?
|
| Ifosfamide | 3 | 2018 | 357 | 0.270 |
Why?
|
| Deoxycytidine | 6 | 2018 | 1390 | 0.260 |
Why?
|
| Antigens, Surface | 1 | 2007 | 303 | 0.260 |
Why?
|
| Bendamustine Hydrochloride | 2 | 2016 | 122 | 0.260 |
Why?
|
| Oligopeptides | 2 | 2021 | 447 | 0.250 |
Why?
|
| Hydroxamic Acids | 4 | 2016 | 454 | 0.250 |
Why?
|
| Physicians | 2 | 2023 | 851 | 0.240 |
Why?
|
| Bortezomib | 3 | 2018 | 543 | 0.240 |
Why?
|
| Radiopharmaceuticals | 4 | 2017 | 1341 | 0.230 |
Why?
|
| Retreatment | 4 | 2018 | 447 | 0.230 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 1948 | 0.230 |
Why?
|
| Radiation Pneumonitis | 2 | 2016 | 313 | 0.220 |
Why?
|
| Carboplatin | 3 | 2018 | 879 | 0.220 |
Why?
|
| Tumor Burden | 3 | 2019 | 2031 | 0.220 |
Why?
|
| Disease Progression | 11 | 2019 | 6840 | 0.210 |
Why?
|
| Melphalan | 5 | 2018 | 875 | 0.210 |
Why?
|
| Disease Management | 3 | 2017 | 1087 | 0.210 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 5099 | 0.210 |
Why?
|
| Radioimmunotherapy | 2 | 2020 | 128 | 0.200 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2020 | 625 | 0.200 |
Why?
|
| Transplantation, Autologous | 9 | 2018 | 2045 | 0.200 |
Why?
|
| Hematologic Diseases | 4 | 2015 | 255 | 0.200 |
Why?
|
| Depsipeptides | 2 | 2019 | 77 | 0.190 |
Why?
|
| Pregnancy | 4 | 2017 | 8107 | 0.190 |
Why?
|
| Algorithms | 1 | 2013 | 3896 | 0.190 |
Why?
|
| Endocarditis | 1 | 2002 | 125 | 0.190 |
Why?
|
| Transplantation Conditioning | 3 | 2016 | 2368 | 0.190 |
Why?
|
| Remission Induction | 9 | 2018 | 3648 | 0.180 |
Why?
|
| Oncologists | 1 | 2023 | 136 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2017 | 1260 | 0.180 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 341 | 0.180 |
Why?
|
| Models, Economic | 1 | 2020 | 102 | 0.170 |
Why?
|
| Radiation Injuries | 3 | 2016 | 1469 | 0.170 |
Why?
|
| beta 2-Microglobulin | 2 | 2018 | 189 | 0.170 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 3842 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1094 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 5 | 2016 | 1320 | 0.160 |
Why?
|
| Mitoxantrone | 2 | 2017 | 227 | 0.160 |
Why?
|
| Piperidines | 2 | 2022 | 1086 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 1229 | 0.160 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2018 | 33 | 0.150 |
Why?
|
| Cohort Studies | 8 | 2018 | 9464 | 0.150 |
Why?
|
| Diagnostic Imaging | 2 | 2017 | 1174 | 0.150 |
Why?
|
| Methotrexate | 5 | 2023 | 1025 | 0.150 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 348 | 0.140 |
Why?
|
| Chemoradiotherapy | 5 | 2018 | 2027 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 189 | 0.140 |
Why?
|
| Quinazolinones | 1 | 2017 | 52 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 1387 | 0.140 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.140 |
Why?
|
| Caregivers | 1 | 2023 | 752 | 0.140 |
Why?
|
| Orbital Neoplasms | 1 | 2019 | 233 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2018 | 609 | 0.140 |
Why?
|
| Vidarabine | 3 | 2017 | 1383 | 0.130 |
Why?
|
| Thalidomide | 3 | 2014 | 595 | 0.130 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 121 | 0.130 |
Why?
|
| Hypothyroidism | 1 | 2018 | 207 | 0.130 |
Why?
|
| Nausea | 2 | 2016 | 540 | 0.130 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2015 | 26 | 0.130 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 67 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 1 | 2002 | 855 | 0.130 |
Why?
|
| Purines | 1 | 2017 | 271 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Abortion, Induced | 1 | 2016 | 92 | 0.130 |
Why?
|
| Interferons | 1 | 2017 | 299 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 965 | 0.130 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 65 | 0.130 |
Why?
|
| Bile Ducts | 1 | 2016 | 114 | 0.130 |
Why?
|
| Breast Neoplasms | 7 | 2018 | 16183 | 0.130 |
Why?
|
| Splenic Neoplasms | 1 | 2016 | 124 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 380 | 0.130 |
Why?
|
| Troponin I | 1 | 2016 | 130 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 529 | 0.120 |
Why?
|
| Postpartum Period | 1 | 2016 | 261 | 0.120 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 4887 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2018 | 671 | 0.120 |
Why?
|
| Organs at Risk | 1 | 2018 | 558 | 0.120 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 812 | 0.120 |
Why?
|
| Lung | 2 | 2016 | 3288 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 257 | 0.120 |
Why?
|
| United States | 10 | 2023 | 15776 | 0.120 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 153 | 0.120 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 210 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 4814 | 0.120 |
Why?
|
| Anthracyclines | 1 | 2016 | 339 | 0.110 |
Why?
|
| Dexamethasone | 5 | 2018 | 1507 | 0.110 |
Why?
|
| Pyrimidines | 4 | 2019 | 3662 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 840 | 0.110 |
Why?
|
| Cholestasis | 1 | 2016 | 207 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2016 | 327 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 682 | 0.110 |
Why?
|
| Fatigue | 3 | 2014 | 1278 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 212 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 473 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 862 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2015 | 208 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 742 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2018 | 6752 | 0.110 |
Why?
|
| Time Factors | 5 | 2018 | 12953 | 0.100 |
Why?
|
| Vomiting | 1 | 2014 | 362 | 0.100 |
Why?
|
| Monocytes | 1 | 2016 | 779 | 0.100 |
Why?
|
| Antigens, CD20 | 1 | 2013 | 207 | 0.100 |
Why?
|
| Maytansine | 1 | 2012 | 40 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2391 | 0.100 |
Why?
|
| Bone Resorption | 1 | 2012 | 136 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4318 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 308 | 0.100 |
Why?
|
| Immunotoxins | 1 | 2012 | 120 | 0.100 |
Why?
|
| Lactams, Macrocyclic | 1 | 2012 | 90 | 0.100 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 190 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2015 | 721 | 0.100 |
Why?
|
| Benzoquinones | 1 | 2012 | 110 | 0.100 |
Why?
|
| Heart | 1 | 2018 | 1159 | 0.100 |
Why?
|
| Urate Oxidase | 1 | 2011 | 43 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 1265 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2019 | 2231 | 0.100 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2011 | 40 | 0.100 |
Why?
|
| Quality of Life | 3 | 2023 | 4772 | 0.100 |
Why?
|
| Indoles | 2 | 2013 | 1026 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 205 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1081 | 0.090 |
Why?
|
| Gout Suppressants | 1 | 2011 | 72 | 0.090 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 354 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2012 | 264 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 191 | 0.090 |
Why?
|
| Child | 7 | 2024 | 30466 | 0.090 |
Why?
|
| Cytarabine | 4 | 2018 | 2013 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2018 | 1425 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2016 | 718 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2011 | 927 | 0.090 |
Why?
|
| Neoplasms | 4 | 2017 | 15902 | 0.080 |
Why?
|
| Models, Biological | 1 | 2018 | 3187 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 2073 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 794 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2016 | 1928 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2011 | 354 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 7779 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 1440 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 4958 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1840 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 510 | 0.080 |
Why?
|
| Busulfan | 3 | 2018 | 792 | 0.080 |
Why?
|
| Pyrroles | 1 | 2012 | 587 | 0.070 |
Why?
|
| Age Factors | 2 | 2014 | 5449 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2012 | 754 | 0.070 |
Why?
|
| Risk Factors | 7 | 2020 | 17824 | 0.070 |
Why?
|
| Genomics | 1 | 2018 | 2834 | 0.070 |
Why?
|
| Genetic Therapy | 2 | 2006 | 1713 | 0.070 |
Why?
|
| Pentostatin | 2 | 2019 | 121 | 0.070 |
Why?
|
| Incidence | 4 | 2018 | 5806 | 0.070 |
Why?
|
| Imidazoles | 1 | 2012 | 1056 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 2475 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5138 | 0.070 |
Why?
|
| Bone Marrow Diseases | 2 | 2019 | 186 | 0.070 |
Why?
|
| Autografts | 2 | 2018 | 179 | 0.070 |
Why?
|
| Yttrium Radioisotopes | 2 | 2020 | 210 | 0.070 |
Why?
|
| Benzamides | 1 | 2011 | 1878 | 0.070 |
Why?
|
| Biopsy | 3 | 2019 | 3384 | 0.070 |
Why?
|
| Neutropenia | 3 | 2017 | 1006 | 0.070 |
Why?
|
| Amifostine | 1 | 2006 | 99 | 0.070 |
Why?
|
| Drugs, Investigational | 1 | 2007 | 129 | 0.060 |
Why?
|
| Trastuzumab | 2 | 2005 | 743 | 0.060 |
Why?
|
| Mediastinum | 2 | 2019 | 276 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1542 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 1580 | 0.060 |
Why?
|
| Lung Diseases | 3 | 2017 | 751 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 7892 | 0.060 |
Why?
|
| Glycolysis | 2 | 2019 | 531 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 2616 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3939 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 371 | 0.060 |
Why?
|
| North America | 2 | 2018 | 337 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2013 | 1603 | 0.060 |
Why?
|
| Radiotherapy Dosage | 3 | 2017 | 3999 | 0.060 |
Why?
|
| Holistic Nursing | 1 | 2003 | 1 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 7883 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 4470 | 0.060 |
Why?
|
| Education, Nursing, Continuing | 1 | 2003 | 25 | 0.060 |
Why?
|
| Transplantation, Homologous | 3 | 2016 | 3041 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3343 | 0.060 |
Why?
|
| Indians, North American | 1 | 2003 | 88 | 0.050 |
Why?
|
| Inservice Training | 1 | 2003 | 73 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 5906 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 661 | 0.050 |
Why?
|
| Radiometry | 2 | 2019 | 1017 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2016 | 1568 | 0.050 |
Why?
|
| Interleukins | 1 | 2004 | 341 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2006 | 1140 | 0.050 |
Why?
|
| Liver | 2 | 2016 | 3069 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2016 | 2316 | 0.050 |
Why?
|
| HIV Infections | 1 | 2014 | 2153 | 0.050 |
Why?
|
| Patient Preference | 1 | 2024 | 228 | 0.050 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2017 | 409 | 0.050 |
Why?
|
| Polyethylene Glycols | 2 | 2015 | 651 | 0.050 |
Why?
|
| Risk | 2 | 2016 | 1937 | 0.050 |
Why?
|
| Apoptosis | 2 | 2006 | 7741 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 2269 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4955 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2018 | 13378 | 0.050 |
Why?
|
| Biomarkers | 3 | 2016 | 5046 | 0.050 |
Why?
|
| Genes, bcl-2 | 2 | 2014 | 172 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1577 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2013 | 1434 | 0.040 |
Why?
|
| Anemia | 2 | 2017 | 725 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 1821 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 1581 | 0.040 |
Why?
|
| Propensity Score | 1 | 2023 | 768 | 0.040 |
Why?
|
| Prevalence | 2 | 2019 | 3351 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 10695 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 4944 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 2 | 2015 | 598 | 0.040 |
Why?
|
| Bone Marrow | 2 | 2017 | 2437 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 121 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 236 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 2389 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 4043 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2012 | 3553 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 134 | 0.040 |
Why?
|
| Reed-Sternberg Cells | 1 | 2018 | 46 | 0.040 |
Why?
|
| Carmustine | 1 | 2018 | 224 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 729 | 0.040 |
Why?
|
| Cerebroside-Sulfatase | 1 | 1996 | 8 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 31 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2016 | 34 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2018 | 286 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2018 | 298 | 0.030 |
Why?
|
| Therapeutics | 1 | 2016 | 31 | 0.030 |
Why?
|
| Procarbazine | 1 | 2016 | 71 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 2016 | 71 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 655 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 2450 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 5309 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 179 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 4956 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 150 | 0.030 |
Why?
|
| Isochromosomes | 1 | 2016 | 55 | 0.030 |
Why?
|
| Orbit | 1 | 2017 | 209 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 224 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 185 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2017 | 574 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2016 | 172 | 0.030 |
Why?
|
| Health Status | 1 | 2019 | 630 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2016 | 175 | 0.030 |
Why?
|
| Czech Republic | 1 | 2015 | 18 | 0.030 |
Why?
|
| Aurora Kinase A | 1 | 2016 | 210 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 212 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2017 | 751 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2016 | 173 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 47 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 360 | 0.030 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2015 | 35 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 553 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 237 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 68 | 0.030 |
Why?
|
| Poland | 1 | 2015 | 67 | 0.030 |
Why?
|
| Genes, Immunoglobulin | 1 | 2015 | 85 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2016 | 234 | 0.030 |
Why?
|
| France | 1 | 2015 | 120 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 240 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 252 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 748 | 0.030 |
Why?
|
| Mass Screening | 1 | 2003 | 1545 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 151 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 186 | 0.030 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 14832 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 329 | 0.030 |
Why?
|
| Bilirubin | 1 | 2016 | 226 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 191 | 0.030 |
Why?
|
| Spasm | 1 | 2014 | 58 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 261 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2014 | 87 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 309 | 0.030 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2014 | 19 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 126 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 2650 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1996 | 650 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1047 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 55 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 6430 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 74 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2013 | 69 | 0.030 |
Why?
|
| Topotecan | 1 | 2014 | 248 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 175 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 550 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2018 | 560 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 678 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 271 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2016 | 770 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 2586 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2016 | 366 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2017 | 759 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 678 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 337 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 686 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 1405 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 372 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 1996 | 563 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2003 | 1900 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 1512 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 668 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 712 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 870 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 2056 | 0.020 |
Why?
|
| Consensus | 1 | 2016 | 1100 | 0.020 |
Why?
|
| Alopecia | 1 | 2012 | 123 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2012 | 172 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1742 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2012 | 228 | 0.020 |
Why?
|
| Uric Acid | 1 | 2011 | 117 | 0.020 |
Why?
|
| Palliative Care | 1 | 2002 | 2173 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 959 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2308 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2015 | 512 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1427 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 516 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2026 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2006 | 1496 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 467 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1217 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2012 | 622 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1058 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1285 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 689 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2016 | 12087 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3993 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 741 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 2101 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2015 | 1539 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 2810 | 0.020 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2006 | 75 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 4561 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2353 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 5153 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2006 | 188 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 374 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 7632 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 5757 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 537 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 6485 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 1655 | 0.010 |
Why?
|
| Public Health Nursing | 1 | 2003 | 1 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3107 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 5658 | 0.010 |
Why?
|
| Cultural Characteristics | 1 | 2003 | 67 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 12019 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5773 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 521 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 5000 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2003 | 601 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 1856 | 0.010 |
Why?
|
| beta Catenin | 1 | 2004 | 681 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 1125 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 16987 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 5336 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 15900 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 1620 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 61714 | 0.010 |
Why?
|
| Blood Protein Electrophoresis | 1 | 1996 | 11 | 0.010 |
Why?
|
| Leukodystrophy, Metachromatic | 1 | 1996 | 6 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 9039 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 7236 | 0.010 |
Why?
|
| Pedigree | 1 | 1996 | 2043 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1996 | 2357 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1996 | 2165 | 0.000 |
Why?
|
| Mice | 1 | 2004 | 35465 | 0.000 |
Why?
|